Q Biomed Inc. Closes $5.48 Million Public Offering

Company Expects Commercialization and Revenue from its Non-Opioid Pain Palliation Drug in Q2 2018 and Initiation of Multiple Pivotal Clinical Programs in 2018 NEW YORK, February 1, 2018 /PRNewswire/ — Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology...